Rift Valley fever phlebovirus Nucleocapsid Protein (RVFV-NP) | NCP0154

Rift Valley fever phlebovirus Nucleocapsid Protein (RVFV-NP) | NCP0154 | Gentaur UK, US & Europe Distribution

Host: His-tag

Reactivity: E. coli Expression

Application: Reseach

Background: Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that was first discovered in Kenya in 1930 and is now endemic throughout multiple African countries and the Arabian Peninsula. RVF virus primarily infects domestic livestock (sheep, goats, cattle) causing high rates of neonatal mortality and abortion, with human infection resulting in a wide variety of clinical outcomes, ranging from self-limiting febrile illness to life-threatening haemorrhagic diatheses, and miscarriage in pregnant women. Since its discovery, RVF has caused many outbreaks in Africa and the Arabian Peninsula with major impacts on human and animal health. However, options for the control of RVF outbreaks are limited by the lack of licensed human vaccines or therapeutics.

Concentration: Inclusion body;0.5mol Urea, PH=8

Purification: Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE) .

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Carrier:pET30a-RVFV-NP-His (C-term) Virus:Rift Valley fever virus strain MP-12 segment S, complete sequence

Note: For research use only, not for use in diagnostic procedure.

Alternative Name: N/A

Immunogen: N/A